reports
- Kate Heseltine
Treatt - Return to growth in FY23
Treatt’s FY23 results show a significantly improved y-o-y operating performance, delivering revenue and profit growth alongside record cash generation. Sales in H223 were affected by the destocking of inventory from clients, although management notes early signs of this reversing. Particularly strong growth came from Treatt’s new markets segment (Coffee, China and Treattzest), up 61% y-o-y. Record cash generation resulted in net debt more than halving to £10.4m. Management is focusing on volume ...
- Kate Heseltine
Treatt - FY23 profits in line despite headwinds
Treatt’s FY23 trading update demonstrated a resilient performance despite the tougher trading environment towards the end of the year. Revenue growth of c 5% (to c £147m) has been driven by price increases, which have mitigated inflationary pressures and supported margins. Sales in H223 slowed due to destocking as clients reduced inventories, although management notes early signs that this is reversing. New markets (Coffee, China and Treattzest citrus) displayed particularly strong growth, with ...
- Kate Heseltine
Treatt - A strong start to the year
Treatt’s H123 results demonstrate that the business is back to greater stability and resilience. The growth was particularly impressive in Citrus, Coffee and China, and management is quietly confident about the rest of the year. We continue to believe that risk lies to the upside in terms of market expectations. Growth in H1 was driven by price increases, which offset inflationary pressures and supported margins. Cost control and efficiency measures are ongoing, and cash flow was strong, as high...
- Kate Heseltine
Treatt - Strong revenue growth, profit in line
After the usual slower start to the year, Treatt has had a strong Q2; H123 sales growth was 8.5% at constant currency. Momentum is expected to continue into H2, with current sales growth mainly skewed to price as Treatt continues to recover increased costs, though there was also a small contribution from an improvement in mix. Citrus continued to perform strongly as Treatt pursues its strategy of moving away from the lower-margin products. We raise our FY23 sales forecasts to reflect the strong ...
Treatt Plc: 1 director
A director at Treatt Plc maiden bought 6,550 shares at 551p and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Kate Heseltine
Treatt - Rebuilding confidence
Treatt’s FY22 results were in line with the revised guidance issued in August. Management once again explained the steps that have been taken to improve processes around sales pricing and cost recovery, with new FX management systems already implemented. Coffee was reported as a standalone segment for the first time as revenues broke through £1m. While it is still early, the company expects coffee to provide significant growth in the years ahead. Management remains optimistic despite the dampene...
- Kate Heseltine
Treatt - Holding steady
Treatt’s FY22 trading update was in line with the reduced guidance issued on 15 August, ie adjusted PBT of £15–15.3m. Revenue growth of 13% is in line with market expectations and the dividend policy remains unchanged. Revenue growth spanned all categories with the exception of tea, as per the August statement. Health and Wellness and Synthetic Aroma witnessed particularly strong growth. The over-hedging, which was highlighted in August and caused part of the downgrade to profits, has now been c...
- Kate Heseltine
Treatt - Rebasing expectations
Treatt’s unexpected trading statement of 15 August reduced FY22 pre-tax profit guidance to a range of £15.0–15.3m versus our previous forecast of £21.9m (pre-exceptional rather than normalised). The main drivers of the downgrade were lower sales in tea, driven by weak consumer confidence in the United States; over-hedging, which resulted in losses crystallising due to the devaluation of sterling against the US dollar; continued input cost inflation; and slower growth in China owing to ongoing CO...
Treatt (TET): New facility to drive growth
Edison Investment Research Limited Treatt (TET): New facility to drive growth 11-Jul-2022 / 07:00 GMT/BST London, UK, 11 July 2022 Treatt (TET): New facility to drive growth Treatt has performed consistently well over the last few years, as it has moved from a commodity trading house to a partner and provider of advanced ingredients solutions. Following its successful expansion of capacity in the United States, it relocated its UK headquarters and manufacturing capability, with almost all staff now working from the new site. This should mark an inflection point for the busin...
- Kate Heseltine
Treatt - New facility to drive growth
Treatt has performed consistently well over the last few years, as it has moved from a commodity trading house to a partner and provider of advanced ingredients solutions. Following its successful expansion of capacity in the United States, it relocated its UK headquarters and manufacturing capability, with almost all staff now working from the new site. This should mark an inflection point for the business as the new facility is significantly more automated, allowing for greater efficiencies. T...
- Kate Heseltine
Treatt - Upgrading revenue forecasts
Treatt has witnessed another good performance: H1 revenue grew by an impressive 9%, with growth across five of Treatt’s six categories. Management has upgraded its revenue growth expectations for the year to 15% and sees pre-tax profit being on track to meet current consensus of £21.7m, as the company continues to invest for the future. We upgrade our revenue forecasts in line with guidance, though our profit forecasts remain broadly unchanged. As per previous guidance, H2 is expected to witness...
- Kate Heseltine
Treatt - Reverting to a normal split
Treatt has continued to perform well, with the good business momentum continuing into H122. As previously flagged and as consumers emerge from the pandemic, the performance in FY22 is expected to return to more normal beverage trends, with H2 seasonally stronger than H1, and a shift back to on-trade beverage consumption. In addition, the higher-margin healthier living categories are also expected to perform better in H2, which will be reflected in the split of profitability. We raise our revenue...
- Kate Heseltine
Treatt - Strong start
As has become customary, Treatt has once again made a good start to the financial year and grown across multiple categories. This year’s adjusted PBT is likely to revert to a more normal H1/H2 weighting, as previously indicated by the company. This comes against a backdrop of an unusually strong H1 in the prior year. The move to the UK headquarters is progressing as planned. We leave our estimates unchanged at this early stage in the year, but note the board’s confident outlook.
- Kate Heseltine
Treatt - Strong start
As has become customary, Treatt has once again made a good start to the financial year and grown across multiple categories. This year’s adjusted PBT is likely to revert to a more normal H1/H2 weighting, as previously indicated by the company. This comes against a backdrop of an unusually strong H1 in the prior year. The move to the UK headquarters is progressing as planned. We leave our estimates unchanged at this early stage in the year, but note the board’s confident outlook.
TREATT PLC sees a downgrade to Neutral on account of less fundamental ...
The independent financial analyst theScreener just lowered the general evaluation of TREATT PLC (GB), active in the Food Products industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date January 25, 2022, the closing price was GBp 1,140.00 and its target pri...
- Kate Heseltine
Treatt - Looking ahead to a new level
Treatt has once again posted a strong performance in FY21, delivering its ninth consecutive year of increased adjusted PBT. Healthier living remains an important driver of revenue and margin expansion, with group gross margins up an impressive 480bp during the year. Investment in the business continues, with the installation and commissioning of machinery at the new UK site expected by mid-2022, and the transfer of manufacturing equipment from the old facility to be completed by mid-2023. The to...
- Kate Heseltine
Treatt - Looking ahead to a new level
Treatt has once again posted a strong performance in FY21, delivering its ninth consecutive year of increased adjusted PBT. Healthier living remains an important driver of revenue and margin expansion, with group gross margins up an impressive 480bp during the year. Investment in the business continues, with the installation and commissioning of machinery at the new UK site expected by mid-2022, and the transfer of manufacturing equipment from the old facility to be completed by mid-2023. The to...
- Kate Heseltine
Treatt - Positive momentum continues
Treatt has had yet another strong year, with momentum in the business continuing. Revenue growth was 14% during the year, or 18% at constant currency, and was driven by continued strength in the healthier living segments, although slightly below our forecasts. Margins also continued to benefit from the positive mix as Treatt’s products increasingly move towards more value-added solutions. FY21 PBT is still expected to be in line with prior guidance.
- Kate Heseltine
Treatt - Positive momentum continues
Treatt has had yet another strong year, with momentum in the business continuing. Revenue growth was 14% during the year, or 18% at constant currency, and was driven by continued strength in the healthier living segments, although slightly below our forecasts. Margins also continued to benefit from the positive mix as Treatt’s products increasingly move towards more value-added solutions. FY21 PBT is still expected to be in line with prior guidance.
Treatt (TET): Sweet upgrades
Edison Investment Research Limited Treatt (TET): Sweet upgrades 19-May-2021 / 07:00 GMT/BST London, UK, 19 May 2021 Treatt (TET): Sweet upgrades Treatt has once again demonstrated the strength of its business model, with another excellent set of results, and yet another upgrade to guidance. The performance continues to be testament to the management and culture of the business, which has been transformed under CEO Daemmon Reeve's nine years at the helm. Both sales and profit performance are impressive, and we once again raise our forecasts, as the 'healthier' categories cont...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.